★
TXG
10X Genomics Inc · Life Sciences Tools & Services
FCF$130mC
Rev+5.2%C+
D/E0.11A-
P/S4.7xB
PEG——
67Score
$24.621Y Target$33.24Near-term target
5Y Target$49.52Compound horizon
10Y Target$128.86Long-dated conviction
FCF$130mTTM · 12/25C
FCF $130m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 12/25).
Rev+5.2%TTM YoYC+
Revenue +5.2% — steady but below market-beating range · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.11totalA-
D/E 0.11 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S4.7xB
P/S 4.7x — in line with software/tech peers
PEG—proxy—
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Life Sciences Tools & Services · market cap $3.1b. 7% off the 52-week high of $26.45.
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Currently unprofitable (margin -3.5%) — path to GAAP profitability is the core thesis risk. Beta 2.06 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -3% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $33.24 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $49.52 — requires the platform / technology to reach commercial scale. 10 yr $128.86 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · TXG
Shares to buy
81
Position size
$1,994
4.0% of portfolio
Stop price
$18.46
25% below $24.62
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.